Search

Your search keyword '"Son, Mary Beth F."' showing total 67 results

Search Constraints

Start Over You searched for: Author "Son, Mary Beth F." Remove constraint Author: "Son, Mary Beth F." Database MEDLINE Remove constraint Database: MEDLINE
67 results on '"Son, Mary Beth F."'

Search Results

2. Racial Disparities and Achievement of the Low Lupus Disease Activity State: A CARRA Registry Study.

Catalog

Books, media, physical & digital resources

3. Features of hyperinflammation link the biology of EBV infection and cytokine storm syndromes.

4. Kawasaki disease: contemporary perspectives.

5. Real-world application of the pediatric Glucocorticoid Toxicity Index in childhood-onset lupus.

6. Severe Features of Systemic Juvenile Idiopathic Arthritis in Patients With Congenital Heart Disease.

7. Racial and Ethnic Composition of Populations Served by Freestanding Children's Hospitals and Disparities in Outcomes of Pediatric Lupus.

8. The RECOVERY trial of PIMS-TS: important lessons from the pandemic.

10. Updated Case Definition of MIS-C and Implications for Clinical Care.

11. Health Equity Implications of Missing Data Among Youths With Childhood-Onset Systemic Lupus Erythematosus: A Proof-of-Concept Study in the Childhood Arthritis and Rheumatology Research Alliance Registry.

12. Incidence and Risk Factors for Eosinophilia and Lung Disease in Biologic-Exposed Children With Systemic Juvenile Idiopathic Arthritis.

13. Development of a Screening Algorithm for Lung Disease in Systemic Juvenile Idiopathic Arthritis.

14. A case of neonatal sweet syndrome associated with mevalonate kinase deficiency.

15. Real-world use and outcomes of belimumab in childhood-onset lupus: A single-center retrospective study.

16. Insurance Status and Tumor Necrosis Factor Inhibitor Initiation Among Children With Juvenile Idiopathic Arthritis in the CARRA Registry.

17. Variation in Early Anakinra Use and Short-Term Outcomes in Multisystem Inflammatory Syndrome in Children.

18. Neurological and Psychological Sequelae Associated With Multisystem Inflammatory Syndrome in Children.

19. Immunomodulatory Therapy for MIS-C.

20. Clinical Course Associated with Aseptic Meningitis Induced by Intravenous Immunoglobulin for the Treatment of Multisystem Inflammatory Syndrome in Children.

23. Disordered T cell-B cell interactions in autoantibody-positive inflammatory arthritis.

25. Postdischarge Glucocorticoid Use and Clinical Outcomes of Multisystem Inflammatory Syndrome in Children.

26. Association of Race and Ethnicity With Medication Use for Pediatric Lupus in the Childhood Arthritis and Rheumatology Research Alliance Registry.

27. Longitudinal assessment of preparation for care transition among adolescents and young adults with rheumatologic disease: a single-center pilot study.

28. SARS-CoV-2-specific T cell responses in patients with multisystem inflammatory syndrome in children.

29. Treatment of Multisystem Inflammatory Syndrome in Children: Understanding Differences in Results of Comparative Effectiveness Studies.

30. An Evidence-Based Guideline Improves Outcomes for Patients With Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome.

31. Racial Disparities in Renal Outcomes Over Time Among Hospitalized Children With Systemic Lupus Erythematosus.

34. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3.

35. An integrated framework for identifying clinical-laboratory indicators for novel pandemics: COVID-19 and MIS-C.

36. An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2.

37. Data-driven clustering identifies features distinguishing multisystem inflammatory syndrome from acute COVID-19 in children and adolescents.

39. Th1 polarization defines the synovial fluid T cell compartment in oligoarticular juvenile idiopathic arthritis.

40. Multisystem Inflammatory Syndrome in Children - Initial Therapy and Outcomes.

41. Reply.

42. Multiple Emergency Department Visits for a Diagnosis of Kawasaki Disease: An Examination of Risk Factors and Outcomes.

43. Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome.

44. Mistaken MIS-C: A Case Series of Bacterial Enteritis Mimicking MIS-C.

45. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2.

46. Cyclophosphamide use in treatment of refractory Kawasaki disease with coronary artery aneurysms.

47. Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19.

48. Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach.

49. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children.

50. Atrioventricular Block in Children With Multisystem Inflammatory Syndrome.